hydroxyproline has been researched along with Bone Diseases, Metabolic in 45 studies
Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.
hydroxyproline : A proline derivative that is proline substituted by at least one hydroxy group.
Bone Diseases, Metabolic: Diseases that affect the METABOLIC PROCESSES of BONE TISSUE.
| Excerpt | Relevance | Reference |
|---|---|---|
| ") infusion of 5 mg alendronate was studied in ten patients with Paget's disease, six patients with primary hyperparathyroidism and ten osteopenic postmenopausal women." | 7.69 | Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone. ( Adami, S; Bertoldo, F; Braga, B; Dorizzi, R; Gatti, D; Locascio, V; Mian, M; Rossini, M; Zamberlan, N, 1994) |
| "We studied bone mineral metabolism changes complicated by acute gastroenteritis in a clinical acute metabolic acidosis milieu where we observed hypercalcemia, hypercalciuria, and elevated urinary hydroxyproline excretion." | 3.72 | Bone mineral changes in acute metabolic acidosis due to acute gastroenteritis. ( Mungan, NO; Ozer, G; Topaloglu, AK; Yildizdas, D; Yuksel, B, 2004) |
| ") infusion of 5 mg alendronate was studied in ten patients with Paget's disease, six patients with primary hyperparathyroidism and ten osteopenic postmenopausal women." | 3.69 | Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone. ( Adami, S; Bertoldo, F; Braga, B; Dorizzi, R; Gatti, D; Locascio, V; Mian, M; Rossini, M; Zamberlan, N, 1994) |
| " The present study was undertaken to determine whether androgen blockade with flutamide (15 mg/kg body weight orally daily) would influence bone turnover or bone composition (1) in female rats with intact ovaries and (2) in rats made estrogen-deficient with the luteinizing hormone releasing hormone (LHRH) agonist, buserelin (25 micrograms/kg body weight per day SC)." | 3.68 | Flutamide-mediated androgen blockade evokes osteopenia in the female rat. ( Gold, E; Goulding, A, 1993) |
| " In young women estrogen-deficiency bone loss is a clinical problem associated with the use of luteinizing hormone releasing hormone (LHRH) agonists, such as buserelin, to treat endometriosis." | 3.68 | Preventive effects of clomiphene citrate on estrogen-deficiency osteopenia elicited by LHRH agonist administration in the rat. ( Fisher, L; Goulding, A, 1991) |
| "Free hydroxyproline was measured in plasma of 67 normal subjects and in 70 patients with bone disease including primary hyperparathyroidism (n = 19), osteoporosis (n = 18), Paget's disease (n = 14), cancer involving bone (n = 8), chronic renal failure (n = 6), and osteomalacia (n = 6), and osteomalacia (n = 5)." | 3.67 | Clinical significance of free plasma hydroxyproline measurement in metabolic bone disease. ( Antonelli, R; Mazzuoli, G; Minisola, S, 1985) |
| "Biochemical markers of bone resorption that reflect osteoclast activity and/or collagen degradation provide a new and potentially important clinical tool for the assessment and monitoring of bone metabolism." | 2.42 | Urine products of bone breakdown as markers of bone resorption and clinical usefulness of urinary hydroxyproline: an overview. ( Karaca, I; Karacaer, O; Simsek, B, 2004) |
| "Twenty-eight patients with postmenopausal osteoporosis (PMO), 32 patients with postmenopausal osteopenia and 30 healthy control subjects (postmenopausal non-osteoporosis) were included in this study." | 1.39 | The relationship between fibroblast growth factor 23 and osteoporosis in postmenopausal women. ( Abali, R; Celik Guzel, E; Celik, E; Guzel, S; Guzelant, AY; Kuçukyalcin, V, 2013) |
| "Osteoporosis was considered as a factor in spinal bone mineral density with a Z-score below 2 or at least one vertebral fracture." | 1.30 | Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. ( Guañabens, N; Martinez de Osaba, MJ; Monegal, A; Muñoz-Gómez, J; Navasa, M; Peris, P; Pons, F; Rimola, A; Rodés, J, 1997) |
| "Osteoporosis is a common disease among patients undergoing transplantation." | 1.30 | Reduction of bone mass in women after bone marrow transplantation. ( Arranz, R; Carmona, L; Carvajal, I; Castañeda, S; Díaz, A; García-Vadillo, A, 1997) |
| "Active hyperthyroidism is associated with reduced bone mass." | 1.30 | Identification of metabolic bone disease in patients with endogenous hyperthyroidism: role of biological markers of bone turnover. ( Escobar-Jiménez, F; Jódar Gimeno, E; Luna del Castillo, JD; Muñoz-Torres, M; Oleà, N; Quesada Charneco, M, 1997) |
| "We examined 60 IDDM patients (30 women without menstruation disturbances; 30 men; age 25-36 years old)." | 1.30 | [Microalbuminuria as a risk factor for diabetic osteopathy in patients with IDDM and renal sufficiency]. ( Goliat, E; Lipińska, A; Marusza, W; Ostrowski, K, 1998) |
| "The diagnostic criterion for postmenopausal osteoporosis was a bone mineral density (BMD) (Hologic QDR-1000) in lumbar spine and/or femoral neck more than 2 SD below the mean value corresponding to an age- and sex-matched healthy control group." | 1.29 | New biochemical markers of bone resorption derived from collagen breakdown in the study of postmenopausal osteoporosis. ( de la Piedra, C; Diaz Diego, EM; Diaz Martin, MA; Disla, T; Guerrero, R; Rapado, A, 1996) |
| "Tamoxifen citrate is an estrogen agonist/antagonist which protects the skeleton from osteopenia when ovarian hormones are depleted." | 1.28 | Tamoxifen in the rat prevents estrogen-deficiency bone loss elicited with the LHRH agonist buserelin. ( Feng, W; Gold, E; Goulding, A, 1992) |
| "Significant osteopenia was present only in group 3 (P less than 0." | 1.28 | 17 beta-estradiol protects rats from osteopenia associated with administration of the luteinising hormone releasing hormone (LHRH) agonist, buserelin. ( Fisher, L; Goulding, A, 1991) |
| "Parameters reflecting bone resorption in od/od rats were reduced in the distal femoral metaphysis, but were similar to those of controls in the tail vertebrae." | 1.28 | Bone histomorphometric analysis for the cause of osteopenia in vitamin C-deficient rat (ODS rat). ( Fujita, T; Fukase, M; Tsunenari, T, 1991) |
| "To determine whether the osteopenia of rheumatoid arthritis (RA) is due to reduction of trabecular bone mass (TBV) and/or cortical width (CW), we evaluated these parameters by bone histomorphometry; we also measured the calciotropic hormones parathormone(PTH) and calcitonin (CT), vitamin D [25(OH)D] and the biological markers of bone remodeling in a group of patients with RA." | 1.28 | Osteopenia in rheumatoid arthritis: a biochemical, hormonal and histomorphometric study. ( Cabranes, JA; Gomez-Castresana, F; Hernandez, ER; Rico, H; Valor, R; Yague, M, 1990) |
| "Using microdensitometry analysis, osteopenia was found in 25% of the anticonvulsant therapy group, but it was not observed in the control group." | 1.28 | Increased circulating levels of gamma-carboxyglutamic acid-containing protein and decreased bone mass in children on anticonvulsant therapy. ( Ishida, H; Kato, H; Kiyohara, K; Nozawa, M; Ogata, K; Seino, Y; Takeshita, N; Tanaka, H; Tsutsumi, C, 1989) |
| "Therefore the pathogenesis of osteopenia in type 1 DM remains unclear, and requires further investigation." | 1.28 | Study of bone loss in diabetes mellitus type 1. ( Hawkins, F; Larrodera, L; Leon, M; Lledo, G, 1989) |
| "Sodium chloride loads induce osteopenia in the rat." | 1.27 | Effects of dietary NaCl supplementation on bone synthesis of hydroxyproline, urinary hydroxyproline excretion and bone 45Ca uptake in the rat. ( Gold, E; Goulding, A, 1988) |
| "Studies of a 63-year-old woman with osteopenia due to systemic mastocytosis are reported." | 1.27 | Osteopenia in systemic mastocytosis: natural history and responses to treatment with inhibitors of bone resorption. ( Beneton, MN; Cundy, T; Darby, AJ; Kanis, JA; Marshall, WJ, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (28.89) | 18.7374 |
| 1990's | 24 (53.33) | 18.2507 |
| 2000's | 4 (8.89) | 29.6817 |
| 2010's | 4 (8.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Celik, E | 1 |
| Guzel, S | 1 |
| Abali, R | 1 |
| Guzelant, AY | 1 |
| Celik Guzel, E | 1 |
| Kuçukyalcin, V | 1 |
| Engelen, MP | 1 |
| Com, G | 1 |
| Deutz, NE | 1 |
| Bezsmertnyĭ, IuO | 1 |
| Potu, BK | 1 |
| Nampurath, GK | 1 |
| Rao, MS | 1 |
| Bhat, KM | 1 |
| Simsek, B | 1 |
| Karacaer, O | 1 |
| Karaca, I | 1 |
| Efstathiadou, Z | 1 |
| Koukoulis, G | 1 |
| Stakias, N | 1 |
| Challa, A | 1 |
| Tsatsoulis, A | 1 |
| Yildizdas, D | 1 |
| Topaloglu, AK | 1 |
| Mungan, NO | 1 |
| Yuksel, B | 1 |
| Ozer, G | 1 |
| Maruyama, K | 1 |
| Rico, H | 2 |
| Cabranes, JA | 2 |
| Paniagua, MC | 1 |
| de Frutos, E | 1 |
| Núñez-Torrón, M | 1 |
| de Pablos, I | 1 |
| Gómez-Castresana, F | 2 |
| Sebert, JL | 1 |
| Cornaille, G | 1 |
| San Juan, MP | 1 |
| Kha, TD | 1 |
| Blotman, F | 1 |
| Simon, L | 1 |
| Eriksen, EF | 1 |
| Brixen, K | 1 |
| Charles, P | 1 |
| Gambacciani, M | 1 |
| Spinetti, A | 1 |
| Piaggesi, L | 1 |
| Cappagli, B | 1 |
| Taponeco, F | 1 |
| Manetti, P | 1 |
| Weiss, C | 1 |
| Teti, GC | 1 |
| La Commare, P | 1 |
| Facchini, V | 1 |
| Vasikaran, SD | 1 |
| McCloskey, EV | 2 |
| Kahn, S | 1 |
| Kanis, JA | 4 |
| Adami, S | 1 |
| Zamberlan, N | 1 |
| Mian, M | 1 |
| Dorizzi, R | 1 |
| Rossini, M | 1 |
| Braga, B | 1 |
| Gatti, D | 1 |
| Bertoldo, F | 1 |
| Locascio, V | 1 |
| Goulding, A | 5 |
| Gold, E | 3 |
| Takeshita, N | 3 |
| Ishida, H | 3 |
| Yamamoto, T | 1 |
| Koh, G | 1 |
| Kurose, T | 1 |
| Tsuji, K | 1 |
| Okamoto, Y | 1 |
| Ikeda, H | 1 |
| Seino, Y | 5 |
| Goliat-Marusza, E | 1 |
| Wardyn, K | 1 |
| Stepniewski, M | 1 |
| Marusza, W | 2 |
| Billip-Tomecka, Z | 1 |
| Ostrowski, K | 2 |
| Schmidt-Gayk, H | 1 |
| Guerrero, R | 1 |
| Diaz Martin, MA | 1 |
| Diaz Diego, EM | 1 |
| Disla, T | 1 |
| Rapado, A | 1 |
| de la Piedra, C | 1 |
| Raue, F | 1 |
| Ziegler, R | 1 |
| Monegal, A | 1 |
| Navasa, M | 1 |
| Guañabens, N | 1 |
| Peris, P | 1 |
| Pons, F | 1 |
| Martinez de Osaba, MJ | 1 |
| Rimola, A | 1 |
| Rodés, J | 1 |
| Muñoz-Gómez, J | 1 |
| Castañeda, S | 1 |
| Carmona, L | 1 |
| Carvajal, I | 1 |
| Arranz, R | 1 |
| Díaz, A | 1 |
| García-Vadillo, A | 1 |
| Jódar Gimeno, E | 1 |
| Muñoz-Torres, M | 1 |
| Escobar-Jiménez, F | 1 |
| Quesada Charneco, M | 1 |
| Luna del Castillo, JD | 1 |
| Oleà, N | 1 |
| Kasugai, Y | 1 |
| Ikegami, A | 1 |
| Matsuo, K | 1 |
| Ohashi, M | 1 |
| Sukamoto, T | 1 |
| Hosoi, T | 1 |
| Ouchi, Y | 1 |
| Orimo, H | 1 |
| Goliat, E | 1 |
| Lipińska, A | 1 |
| Cundy, T | 2 |
| Earnshaw, M | 1 |
| Henderson, RG | 1 |
| Heynen, G | 1 |
| Naik, R | 1 |
| Russell, RG | 1 |
| Smith, R | 1 |
| Woods, CG | 1 |
| Hanson, DA | 1 |
| Weis, MA | 1 |
| Bollen, AM | 1 |
| Maslan, SL | 1 |
| Singer, FR | 1 |
| Eyre, DR | 1 |
| Feng, W | 1 |
| Reginster, JY | 1 |
| Jeugmans-Huynen, AM | 1 |
| Wouters, M | 1 |
| Sarlet, N | 1 |
| McIntyre, HD | 1 |
| Franchimont, P | 1 |
| Krakauer, JC | 1 |
| Kleerekoper, M | 1 |
| Fisher, L | 2 |
| Robins, SP | 1 |
| Black, D | 1 |
| Paterson, CR | 1 |
| Reid, DM | 1 |
| Duncan, A | 1 |
| Seibel, MJ | 1 |
| Tsunenari, T | 1 |
| Fukase, M | 1 |
| Fujita, T | 1 |
| Hernandez, ER | 1 |
| Yague, M | 1 |
| Valor, R | 1 |
| Tanaka, H | 1 |
| Tsutsumi, C | 2 |
| Ogata, K | 1 |
| Kiyohara, K | 1 |
| Kato, H | 1 |
| Nozawa, M | 1 |
| Leon, M | 1 |
| Larrodera, L | 1 |
| Lledo, G | 1 |
| Hawkins, F | 1 |
| Stĕpán, JJ | 1 |
| Lachman, M | 1 |
| Zvĕrina, J | 1 |
| Pacovský, V | 1 |
| Baylink, DJ | 1 |
| Epstein, S | 1 |
| Urwin, GH | 1 |
| Gray, RE | 1 |
| Beneton, MN | 2 |
| Hamdy, NA | 1 |
| Murray, SA | 1 |
| Pavlova, L | 1 |
| Stankova, G | 1 |
| Andonova, S | 1 |
| Taminato, T | 1 |
| Usami, M | 1 |
| Moriuchi, S | 1 |
| Akiyama, Y | 1 |
| Hara, K | 1 |
| Darby, AJ | 1 |
| Marshall, WJ | 1 |
| Minisola, S | 1 |
| Antonelli, R | 1 |
| Mazzuoli, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Leucine-enriched Essential Amino Acid Intake to Optimize Protein Anabolism in Children With Cystic Fibrosis[NCT01172301] | 14 participants (Actual) | Interventional | 2008-07-31 | Completed | |||
| Urine N-telopeptide, Serum Vit D, Parathormone and Calcium Levels in Hyperemesis Gravidarum[NCT02862496] | 60 participants (Anticipated) | Observational [Patient Registry] | 2016-06-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for hydroxyproline and Bone Diseases, Metabolic
| Article | Year |
|---|---|
Urine products of bone breakdown as markers of bone resorption and clinical usefulness of urinary hydroxyproline: an overview.
Topics: Biomarkers; Bone Diseases, Metabolic; Bone Resorption; Collagen; Humans; Hydroxylysine; Hydroxyproli | 2004 |
[Hydroxyproline].
Topics: Biomarkers; Bone Diseases, Metabolic; Chromatography, High Pressure Liquid; Colorimetry; Fibrosis; H | 2004 |
New markers of bone metabolism: clinical use in metabolic bone disease.
Topics: Acid Phosphatase; Age Factors; Alkaline Phosphatase; Biomarkers; Bone Diseases, Metabolic; Bone Rege | 1995 |
Serum and urinary markers of bone remodeling: assessment of bone turnover.
Topics: 1-Carboxyglutamic Acid; Alkaline Phosphatase; Animals; Biomarkers; Bone and Bones; Bone Diseases, Me | 1988 |
2 trials available for hydroxyproline and Bone Diseases, Metabolic
| Article | Year |
|---|---|
Ipriflavone prevents the bone mass reduction in premenopausal women treated with gonadotropin hormone-releasing hormone agonists.
Topics: Adult; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Dose-Response Relationship, Drug; Dou | 1994 |
[Disorders of bone tissue metabolism in patients in diabetes mellitus type one].
Topics: Adolescent; Adult; Bone Density; Bone Diseases, Metabolic; Calcium; Diabetes Mellitus, Type 1; Femal | 1996 |
39 other studies available for hydroxyproline and Bone Diseases, Metabolic
| Article | Year |
|---|---|
The relationship between fibroblast growth factor 23 and osteoporosis in postmenopausal women.
Topics: Alkaline Phosphatase; Biomarkers; Bone Density; Bone Diseases, Metabolic; Bone Remodeling; Calcium; | 2013 |
Increased whole body hydroxyproline production as assessed by a new stable isotope technique is associated with hip and spine bone mineral loss in cystic fibrosis.
Topics: Absorptiometry, Photon; Adolescent; Adult; Anthropometry; Body Composition; Bone Density; Bone Disea | 2014 |
[Metabolic status and bone mineral density in patients with pseudarthrosis of long bones in hyperhomocysteinemia].
Topics: Adult; Bone and Bones; Bone Diseases, Metabolic; Cartilage Oligomeric Matrix Protein; Case-Control S | 2013 |
Effect of Cissus quadrangularis Linn on the development of osteopenia induced by ovariectomy in rats.
Topics: Acid Phosphatase; Alkaline Phosphatase; Alkanes; Animals; Biomarkers; Bone Diseases, Metabolic; Bone | 2011 |
Apolipoprotein E polymorphism is not associated with spinal bone mineral density in peri- and postmenopausal Greek women.
Topics: Adult; Aged; Alleles; Apolipoprotein E4; Apolipoproteins E; Bone Density; Bone Diseases, Metabolic; | 2004 |
Bone mineral changes in acute metabolic acidosis due to acute gastroenteritis.
Topics: Acidosis; Acute Disease; Alkaline Phosphatase; Bone Density; Bone Diseases, Metabolic; Calcium; Chil | 2004 |
[Is phosphodiesterase responsible for bone changes in thyroid dysfunction?].
Topics: Bone Diseases, Metabolic; Female; Humans; Hydroxyproline; Hyperthyroidism; Hypothyroidism; Male; Par | 1983 |
[Fasting urinary excretion of calcium, phosphorus and hydroxyproline in relation to creatinine. Normal values and correlations with 24-hour urine values (author's transl)].
Topics: Bone Diseases, Metabolic; Calcium; Creatinine; Fasting; Female; Humans; Hydroxyproline; Male; Phosph | 1981 |
Intra-individual variation in fasting urinary calcium- and hydroxyproline-creatinine ratios measured in metabolic bone clinic patients as both outpatients and inpatients.
Topics: Aged; Aged, 80 and over; Bone Diseases, Metabolic; Calcium; Creatinine; Fasting; Female; Humans; Hyd | 1994 |
Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone.
Topics: Aged; Alendronate; Alkaline Phosphatase; Bone Diseases, Metabolic; Bone Resorption; Calcium; Diphosp | 1994 |
Flutamide-mediated androgen blockade evokes osteopenia in the female rat.
Topics: Androgens; Animals; Body Weight; Bone Density; Bone Diseases, Metabolic; Buserelin; Female; Flutamid | 1993 |
Circulating levels and bone contents of bone gamma-carboxyglutamic acid-containing protein in rat models of non-insulin-dependent diabetes mellitus.
Topics: Animals; Blood Glucose; Bone and Bones; Bone Diseases, Metabolic; Calcium; Diabetes Mellitus, Experi | 1993 |
[Laboratory diagnosis of metabolic osteopathy].
Topics: Adult; Aged; Alkaline Phosphatase; Bone Diseases, Metabolic; Calcium; Diagnosis, Differential; Femal | 1996 |
New biochemical markers of bone resorption derived from collagen breakdown in the study of postmenopausal osteoporosis.
Topics: Adult; Aged; Amino Acids; Biomarkers; Bone Diseases, Metabolic; Bone Resorption; Calcium; Collagen; | 1996 |
[Bone metabolism and diseases].
Topics: Adult; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Calcium; Female; Gon | 1996 |
Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation.
Topics: Adult; Bone Density; Bone Diseases, Metabolic; Creatinine; Female; Fractures, Bone; Humans; Hydroxyp | 1997 |
Reduction of bone mass in women after bone marrow transplantation.
Topics: Adolescent; Adult; Biomarkers; Bone Density; Bone Diseases, Metabolic; Bone Marrow Transplantation; | 1997 |
Identification of metabolic bone disease in patients with endogenous hyperthyroidism: role of biological markers of bone turnover.
Topics: Absorptiometry, Photon; Acid Phosphatase; Adult; Alkaline Phosphatase; Biomarkers; Bone Density; Bon | 1997 |
Effects of tibolone (Org OD14) treatment for 3 months on ovariectomy-induced osteopenia in 8-month-old rats on a low-calcium diet: preventive testing for 3 months.
Topics: Administration, Oral; Amino Acids; Anabolic Agents; Animals; Antineoplastic Agents, Hormonal; Biomar | 1998 |
[Microalbuminuria as a risk factor for diabetic osteopathy in patients with IDDM and renal sufficiency].
Topics: Absorptiometry, Photon; Adult; Albuminuria; Alkaline Phosphatase; Bone Density; Bone Diseases, Metab | 1998 |
Treatment of renal bone disease with 1 alpha-hydroxylated derivatives of vitamin D3. Clinical, biochemical, radiographic and histological responses.
Topics: Adolescent; Adult; Alkaline Phosphatase; Bone and Bones; Bone Diseases, Metabolic; Calcium; Child; C | 1979 |
A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine.
Topics: Adolescent; Adult; Aged; Amino Acid Sequence; Amino Acids; Antibodies, Monoclonal; Bone Diseases, Me | 1992 |
Tamoxifen in the rat prevents estrogen-deficiency bone loss elicited with the LHRH agonist buserelin.
Topics: Animals; Body Weight; Bone Diseases, Metabolic; Bone Resorption; Buserelin; Calcium; Disease Models, | 1992 |
The effect of nasal hCT on bone turnover in Paget's disease of bone--implications for the treatment of other metabolic bone diseases.
Topics: Administration, Intranasal; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone Diseases, Metabolic; | 1992 |
Borderline-low serum thyrotropin level is correlated with increased fasting urinary hydroxyproline excretion.
Topics: Aged; Bone Diseases, Metabolic; Calcium; Creatinine; Fasting; Female; Humans; Hydroxyproline; Hyperp | 1992 |
Preventive effects of clomiphene citrate on estrogen-deficiency osteopenia elicited by LHRH agonist administration in the rat.
Topics: Animals; Bone Diseases, Metabolic; Bone Resorption; Buserelin; Calcium; Clomiphene; Endometriosis; E | 1991 |
17 beta-estradiol protects rats from osteopenia associated with administration of the luteinising hormone releasing hormone (LHRH) agonist, buserelin.
Topics: Animals; Bone Diseases, Metabolic; Bone Resorption; Buserelin; Calcium; Calcium Radioisotopes; Estra | 1991 |
Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases.
Topics: Aged; Aged, 80 and over; Amino Acids; Biomarkers; Bone Diseases, Metabolic; Bone Resorption; Collage | 1991 |
Bone histomorphometric analysis for the cause of osteopenia in vitamin C-deficient rat (ODS rat).
Topics: Alkaline Phosphatase; Animals; Ascorbic Acid Deficiency; Body Weight; Bone and Bones; Bone Diseases, | 1991 |
Osteopenia in rheumatoid arthritis: a biochemical, hormonal and histomorphometric study.
Topics: Adult; Aged; Aging; Arthritis, Rheumatoid; Bone and Bones; Bone Diseases, Metabolic; Calcitonin; Cal | 1990 |
Increased circulating levels of gamma-carboxyglutamic acid-containing protein and decreased bone mass in children on anticonvulsant therapy.
Topics: 1-Carboxyglutamic Acid; Adolescent; Alkaline Phosphatase; Anticonvulsants; Bone and Bones; Bone Dise | 1989 |
Study of bone loss in diabetes mellitus type 1.
Topics: Alkaline Phosphatase; Blood Glucose; Blood Proteins; Bone and Bones; Bone Diseases, Metabolic; Bone | 1989 |
Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling.
Topics: Adult; Bone and Bones; Bone Development; Bone Diseases, Metabolic; Calcitonin; Calcium-Binding Prote | 1989 |
Effects of intravenous etidronate disodium on skeletal and calcium metabolism.
Topics: Aged; Bone and Bones; Bone Diseases, Metabolic; Calcium; Etidronic Acid; Female; Humans; Hydroxyprol | 1987 |
Hydroxyprolinuria in vibration disease.
Topics: Adult; Bone Cysts; Bone Diseases, Metabolic; Humans; Hydroxyproline; Middle Aged; Occupational Disea | 1988 |
Effects of dietary NaCl supplementation on bone synthesis of hydroxyproline, urinary hydroxyproline excretion and bone 45Ca uptake in the rat.
Topics: Animals; Biological Transport, Active; Bone and Bones; Bone Diseases, Metabolic; Bone Resorption; Ca | 1988 |
Circulating levels and bone contents of bone gamma-carboxyglutamic acid-containing protein are decreased in streptozocin-induced diabetes. Possible marker for diabetic osteopenia.
Topics: Animals; Bone and Bones; Bone Diseases, Metabolic; Calcium; Calcium-Binding Proteins; Diabetes Melli | 1988 |
Osteopenia in systemic mastocytosis: natural history and responses to treatment with inhibitors of bone resorption.
Topics: Biopsy; Bone and Bones; Bone Diseases, Metabolic; Bone Resorption; Female; Humans; Hydroxyproline; M | 1987 |
Clinical significance of free plasma hydroxyproline measurement in metabolic bone disease.
Topics: Adult; Aged; Amino Acids; Bone Diseases, Metabolic; Female; Humans; Hydroxyproline; Hyperparathyroid | 1985 |